Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types

Susanna A Curtis, MD, Ariadna Forray, MD, Jeanne E. Hendrickson, MD, John D. Roberts, MD

Blood (2019) 134 (Supplement_1): 1028.

https://doi.org/10.1182/blood-2019-129106

Published: 2019

Journal Articles

Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease

Wally R Smith, MD, Daniel Sop, BS,MS, Shirley Johnson, BA, LSW, Thokozeni Lipato, MD, Mica Ferlis, ANP, Caitlin Mcmanus, ANP, Margaret Guy, MD, Sarah Hartigan, MD, Emily Holt, BS, Chantal McHenry, BS, John D. Roberts, MD

Blood (2019) 134 (Supplement_1): 2104.

https://doi.org/10.1182/blood-2019-130441

Published: 2019

Journal Articles

Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease

John D. Roberts, MD, Biree Andemariam, MD, Janis Bozzo, MSN, RN, Cindy Du, BS, Susanna A Curtis, MD, Douglas Latham, Mary Ann Cyr, RN, Lawrence Magras

Blood (2019) 134 (Supplement_1): 517.

https://doi.org/10.1182/blood-2019-124462

Published: 2019

Journal Articles

Medical Marijuana Certification for Patients with Sickle Cell Disease: A Survey Study of Patient's Use and Preferences

Susanna A Curtis, MD, Jonathan Spodick, MA, LCSW, Dana Lew, BS, John D. Roberts, MD

Blood (2018) 132 (Supplement 1): 1094.

https://doi.org/10.1182/blood-2018-99-118345

Published: 2018

Journal Articles

Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease

Susanna A Curtis, MD, Raisa Balbuena-Merle, MD, Lesley Devine, PhD, Daniel Zelterman, John D. Roberts, MD, Jennifer Dearborn-Tomazos, MD MPH, Lauren Sansing, MD MS, Jeanne E. Hendrickson, MD

Blood (2018) 132 (Supplement 1): 1093.

https://doi.org/10.1182/blood-2018-99-117504

Published: 2018

Journal Articles

Medical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell Center

Susanna A Curtis, MD, Dana Lew, BS, Jonathan Spodick, MA, LCSW, John D. Roberts, MD

Blood (2018) 132 (Supplement 1): 858.

https://doi.org/10.1182/blood-2018-99-118290

Published: 2018

Journal Articles

Daily Users of Marijuana with Sickle Cell Disease Report More Severe Pain Crisis Yet Have Similar Rates of Admission to Non-Users

Susanna A Curtis, MD, Michelle Deveaux, Daniel Zelterman, Lesley Devine, PhD, Amanda M Brandow, DO, MS, John D. Roberts, MD

Blood (2017) 130 (Supplement 1): 3559.

https://doi.org/10.1182/blood.V130.Suppl_1.3559.3559

Published: 2017

Journal Articles

Chronic Red Blood Cell Exchange Transfusion Therapy Does Not Impact Hospital Utilization or Ascq-Me Pain Domains in Adults Living with Sickle Cell Disease

Susanna A Curtis, MD, Michelle Deveaux, Daniel Zelterman, Lesley Devine, PhD, Jeanne E. Hendrickson, MD, John D. Roberts, MD, Amanda M Brandow, DO, MS

Blood (2017) 130 (Supplement 1): 3414.

https://doi.org/10.1182/blood.V130.Suppl_1.3414.3414

Published: 2017

Journal Articles

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

Beata Holkova, MD, Maciej Kmieciak, PhD, Prithviraj Bose, MD, Shuo Ma, MD PhD, Amy Kimball, MD PhD, Mary Beth Tombes, RN, Ellen Shrader, BS, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Amanda Garnett Singh, RN, BSN, April Dean, BS, Sarah Conine, PhD, Heidi Sankala, PhD, John D. Roberts, MD, Thomas C. Shea, MD, Steven Grant, MD

Blood (2014) 124 (21): 3050.

https://doi.org/10.1182/blood.V124.21.3050.3050

Published: 2014

Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Prithviraj Bose, MD, Daniel M Sullivan, MD, Rachid Baz, MD, Mary Beth Tombes, RN, Ellen Shrader, Viswanathan Ramakrishnan, PhD, Wen Wan, PhD, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 2959.

https://doi.org/10.1182/blood.V120.21.2959.2959

Published: 2012

Journal Articles

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

Beata Holkova, MD, Prithviraj Bose, MD, Mary Beth Tombes, RN, Ellen Shrader, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Guillermo Garcia-Manero, MD, Steven Grant, MD

Blood (2012) 120 (21): 3588.

https://doi.org/10.1182/blood.V120.21.3588.3588

Published: 2012

Journal Articles

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

Beata Holkova, MD, Thomas C. Shea, MD, Prithviraj Bose, MD, Mary Beth Tombes, RN, Ellen Shrader, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 1794.

https://doi.org/10.1182/blood.V120.21.1794.1794

Published: 2012

Journal Articles

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Lubomir Sokol, MD, PhD, Kristy L. Richards, PhD, MD, Samir Parekh, MD, Rebecca Elstrom, MD, Ashraf Z. Badros, MD, Igor Espinoza-Delgado, MD, Michael J. Schell, PhD, Amy Kimball, MD, PhD, Mary Beth Tombes, RN, Ellen Shrader, Heidi Sankala, PhD, Domenico Coppola, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, John D. Roberts, MD, Steven Grant, MD

Blood (2011) 118 (21): 779.

https://doi.org/10.1182/blood.V118.21.779.779

Published: 2011

Journal Articles

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis

Beata Holkova, MD, Mary Beth Tombes, RN, Ellen Shrader, Sheryl S. Cooke, RN, Wen Wan, PhD, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Guillermo Garcia-Manero, Steven Grant, MD

Blood (2011) 118 (21): 2598.

https://doi.org/10.1182/blood.V118.21.2598.2598

Published: 2011

Journal Articles

A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma

Beata Holkova, MD, Ashraf Z. Badros, MD, Robert Geller, MD, Peter M. Voorhees, MD, Adriana Zingone, MD, PhD, Neha Korde, MD, Hui-Yi Lin, PhD, Mary Beth Tombes, RN, Ellen Shrader, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Daniel Sullivan, MD, Ola Landgren, MD, PhD, Steven Grant, MD

Blood (2011) 118 (21): 2931.

https://doi.org/10.1182/blood.V118.21.2931.2931

Published: 2011

NARROW

Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types

Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease

Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease

Medical Marijuana Certification for Patients with Sickle Cell Disease: A Survey Study of Patient's Use and Preferences

Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease

Medical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell Center

Daily Users of Marijuana with Sickle Cell Disease Report More Severe Pain Crisis Yet Have Similar Rates of Admission to Non-Users

Chronic Red Blood Cell Exchange Transfusion Therapy Does Not Impact Hospital Utilization or Ascq-Me Pain Domains in Adults Living with Sickle Cell Disease

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis

A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only